Establishment Labs Hldgs Inc Stock Price, News & Analysis

Establishment Labs Holdings Inc. (NASDAQ: ESTA) submitted the final module for FDA premarket approval of Motiva Implants. The company reported fourth-quarter 2022 sales of $43.8 million, marking a 24.1% year-over-year increase and a new quarterly record. Fourteen million dollars net loss from operations improved from $14.2 million a year ago. For 2023, revenue guidance is set between $200 million and $210 million, reflecting a 24% to 30% growth compared to 2022. Establishment Labs is expanding its Mia Femtech commercialization and expects approval in China in the first half of 2023, enhancing market reach.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ended December 31, 2022, on February 27, 2023, after market close. A conference call is scheduled for 4:30 PM ET that day to discuss the results. Interested participants can join by dialing (877) 407-8037 for U.S. and Canada or (201) 689-8037 for international callers, using conference ID 13736311. Establishment Labs focuses on women's health, offering innovative breast implants branded as Motiva Implants®, with over 2.5 million units delivered since 2010 across 80 countries.

Allurion Technologies and Compute Health Acquisition Corp (NYSE: CPUH) have entered into a business combination agreement, positioning Allurion to become publicly listed as Allurion Technologies, Inc. This innovative company is focused on obesity treatment, featuring the Allurion Gastric Balloon, a swallowable gastric balloon that allows for procedure-less weight loss. Since its inception, Allurion has treated over 100,000 patients worldwide, achieving an average weight loss of 30 pounds. Revenue has surged from $20 million in 2020 to $64 million in 2022. The transaction includes significant investments from RTW Investments and other notable figures.

Establishment Labs (NASDAQ: ESTA) announced preliminary unaudited revenue results for Q4 and FY 2022, projecting Q4 revenue between $43.3 million and $44.3 million, up 23% to 25% year-over-year, and FY 2022 revenue in the range of $161.2 million to $162.2 million, reflecting 27% to 28% growth. Constant currency growth for Q4 is projected at 27% to 29%, and for FY 2022 at 31% to 32%. The company cites strong growth and plans for the expansion of Motiva Implants and the rollout of Mia Femtech™ as key growth drivers.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a strategic partnership with Seishin Plastic and Aesthetic Surgery Clinic in Japan, launching Mia Femtech, a minimally invasive breast aesthetics procedure. This collaboration aims to address dissatisfaction among Japanese women regarding breast aesthetic options, potentially expanding the market significantly. The Mia procedure can enhance breast shape by 1 to 2 cup sizes in just 15 minutes, without general anesthesia. While currently not approved for commercial distribution in the U.S., this launch represents the first of many anticipated in 2023.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12 at 7:30 a.m. Pacific Time. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women’s health technology, focusing on breast aesthetics and reconstruction, and has delivered over 2.5 million Motiva Implants® globally since 2010.

Establishment Labs Holdings (NASDAQ: ESTA) recently announced the approval of Motiva Implants® and the Motiva Flora® tissue expander for use in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA). These products have also secured reimbursement under the Japanese National Health System for post-mastectomy reconstruction. The first patient was treated successfully in November at Nagoya University Hospital. This launch signifies a commitment to enhancing women's health through innovative products backed by clinical data.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported third quarter 2022 sales of $38.2 million, a year-over-year increase of 31.7%. Revenue guidance for 2022 has been narrowed to $158 million to $162 million, reflecting 25% to 28% growth from 2021, with foreign exchange effects expected to reduce revenue by $6.5 million. Gross profit margin improved to 68.1%, while operating expenses rose 27.5% to $36.6 million. The company holds a cash balance of $65.3 million as of September 30, 2022, and plans to commercialize Mia Femtech™ and seek FDA approval for Motiva Implants in early 2023.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Jefferies London Healthcare Conference and the Stephens Annual Investment Conference, both taking place from November 15-17, 2022. CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Jefferies conference on November 15 at 5:00 PM GMT, while Denhoy will speak at the Stephens conference on November 17 at 11:00 AM CT. Live webcasts and archived versions of the presentations will be available on the company's investor relations website.